Dianthus Therapeutics, Inc. /DE/ (DNTH) intrinsic value & 10-year financials
Dianthus Therapeutics, Inc. /DE/ (DNTH) has a Graham intrinsic value of $78.78 per share. At $72.09 on Oct 17, 2026, the stock trades 8% below that value. Over the last 10 fiscal years revenue shrank 15.1% a year to $2.0M, with an average return on invested capital of -56.1%.
- Graham intrinsic value
- $78.78
- Share price (Oct 17, 2026)
- $72.09
- Price vs Graham value
- 8% below
- Market cap
- $2.8B
- Revenue (FY2025)
- $2.0M
- Revenue growth (10-yr CAGR)
- -15.1%
- ROIC (10-yr avg)
- -56.1%
- Free cash flow (FY2025)
- —
DNTH 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $2.0M | -$162.3M | -$4.20 | — | -8739.3% | -46.0% |
| FY2024 | $6.2M | -$85.0M | -$2.55 | — | -1633.7% | -55.4% |
| FY2023 | $2.8M | -$43.6M | -$8.45 | — | -1704.7% | -112.7% |
| FY2022 | — | -$76.5M | -$1.29 | -$67.4M | — | -180.2% |
| FY2021 | — | -$71.1M | -$1.29 | -$60.8M | — | -182.1% |
| FY2020 | — | -$74.9M | -$1.71 | -$64.4M | — | -55.2% |
| FY2019 | $0 | -$76.8M | — | -$60.2M | — | -57.9% |
| FY2018 | $0 | -$57.5M | — | -$49.6M | — | -115.8% |
| FY2017 | $0 | -$35.5M | — | -$24.5M | — | 140.1% |
| FY2016 | $0 | -$9.4M | — | -$6.7M | — | 104.4% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Dianthus Therapeutics, Inc. /DE/ revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Dianthus Therapeutics, Inc. /DE/ has historically struggled to out-earn its cost of capital, averaging just -43.5% ROIC.
Dianthus Therapeutics, Inc. /DE/ capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Dianthus Therapeutics, Inc. /DE/ is modeled at -15.1% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $78.78 per share.